Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Mount Sinai School of Medicine |
---|---|
Information provided by: | Mount Sinai School of Medicine |
ClinicalTrials.gov Identifier: | NCT00263796 |
To study the effect of oxytocin on face processing and response inhibition in autistic adults by fMRI.
Condition | Intervention | Phase |
---|---|---|
Autism |
Drug: Oxytocin |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | An fMRI Study of the Effect of Intravenous Oxytocin vs. Placebo on Response Inhibition and Face Processing in Autism |
Estimated Enrollment: | 30 |
Study Start Date: | March 2006 |
Autism is a developmental disorder affecting approximately 60/10,000 individuals. It is characterized by social and language deficits and repetitive behaviors/restricted interests. Functional imaging is becoming a very useful tool in trying to understand the neurobiology of autism. Oxytocin is a hormone produced by the brain to assist with labor and lactation. Recent evidence suggests that it may be involved in social attachment and in repetitive behaviors. In this project, we will study how oxytocin changes the way the brain of autistic adults processes faces, and deals with response inhibition (the ability to interrupt ongoing responses should they prove ineffective or interfering with attaining a goal). There is currently no functional imaging data assessing the effect of oxytocin on the brain. We will explore the activation patterns in response to oxytocin across circuits involved in social cognition (face fusiform area) and response inhibition (caudate, orbitofrontal and dorsolateral cortex) by administering a specific fMRI task activating those circuits before and during an oxytocin infusion. We will also explore the effect of oxytocin in these areas by administering specific cognitive testing not associated with fMRI before and during oxytocin infusion.
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Kate Stamper, BA | 212-241-7098 | katherine.stamper@mssm.edu |
Contact: Evdokia Anagnostou, MD | 212-241-4229 | evdokia.Anagnostou@mssm.edu |
United States, New York | |
Mount Sinai School of Medicine | Recruiting |
New York, New York, United States, 10029-6574 | |
Principal Investigator: Evdokia Anagnostou, MD |
Principal Investigator: | Evdokia Anagnostou, MD | Mount Sinai School of Medicine |
Study ID Numbers: | GCO # 04-0749 (2) |
Study First Received: | December 7, 2005 |
Last Updated: | April 18, 2007 |
ClinicalTrials.gov Identifier: | NCT00263796 |
Health Authority: | United States: Institutional Review Board |
Developmental Disabilities Child Development Disorders, Pervasive Facies Mental Disorders |
Autistic Disorder Mental Disorders Diagnosed in Childhood Oxytocin |
Oxytocics Therapeutic Uses Physiological Effects of Drugs Reproductive Control Agents Pharmacologic Actions |